NVG 291
Alternative Names: NVG-291; NVG-291-RLatest Information Update: 11 Jun 2025
At a glance
- Originator NervGen Pharma
- Class Antidementias; Neuroprotectants; Peptides; Vascular disorder therapies
- Mechanism of Action Receptor-like protein tyrosine phosphatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Spinal cord injuries
- Phase I Alzheimer's disease; Multiple sclerosis
- Preclinical Stroke
- Research Amyotrophic lateral sclerosis